Since a higher tumor-to-background ratio may contribute to improved tumor margin assessment and rapid tumor-targeting enables tracer injection at the day of surgery, which is often preferred in clinical practice, small molecule PSMA ligands are preferred over antibodies [10, 26]. The gene discussed is FOLH1; the disease is neoplasm.